Seeking Alpha

twritchie416

twritchie416
Send Message
View as an RSS Feed
View twritchie416's Comments BY TICKER:
Latest  |  Highest rated
  • Los Angeles wants out of swap deals with Bank of New York [View news story]
    They held a vote to ask for money back? Kinda sad.
    Aug 13 03:47 PM | Likes Like |Link to Comment
  • North Dakota's new shale problem: radioactive waste [View news story]
    Either way, the EPA will put more pressure on the North Dakota shales and these companies that rely fairly heavily on ND will need a solution to keep the hippies at bay.
    Apr 16 12:29 PM | 6 Likes Like |Link to Comment
  • North Dakota's new shale problem: radioactive waste [View news story]
    Doesn't Abtech (OTCQB:ABHD) have a product that can handle the radioactive element of the waste that is being produced?
    Apr 16 12:24 PM | Likes Like |Link to Comment
  • Corporate Governance And Economic Conditions Make Jos. A. Bank A Short [View article]
    Would the author mind addressing the recent news with JOSB? Just curious as to why BeaconLight Capital feels the stock could move to $70 based on certain changes. Do you think these changes will have a meaningful impact?
    Aug 14 11:40 AM | 1 Like Like |Link to Comment
  • Amarin (AMRN) announces a 21.7M share ADS offering, with a 30-day option to purchase an additional 3.255M ADSs. Citigroup and Jefferies are acting as joint book-runners. Shares -6.5% AH. [View news story]
    You mean should have sold the company when the stock was around $20. Not sure how serious any suitors were at that point but would have paid off much better than driving the stock to $5.
    Jul 8 05:06 PM | 1 Like Like |Link to Comment
  • Amarin (AMRN) announces a 21.7M share ADS offering, with a 30-day option to purchase an additional 3.255M ADSs. Citigroup and Jefferies are acting as joint book-runners. Shares -6.5% AH. [View news story]
    So let me guess, AMRN is having trouble paying the bills for launching Vascepa?
    Jul 8 04:57 PM | 1 Like Like |Link to Comment
  • Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]
    Can't we all agree that the true determinant for the stock is the sales figures for Vascepa. If big pharma hasn't bought AMRN yet, I think they have moved on from NCE status. Companies just want to see how well the product sells.
    Jan 18 03:29 PM | 4 Likes Like |Link to Comment
  • Herbalife (HLF -11.9%) CEO Michael Johnson responds to Bill Ackman's accusation that the company is a 'pyramid scheme' countering that Ackman is improperly trying to manipulate Herbalife's stock and the SEC should take action. Johnson says company is a legitimate business with "millions of customers" and real business model. Ackman's short is about his own business model, not about HLF's. (video[View news story]
    Not questioning you, just curious. What other cases have you noticed?
    Dec 19 04:13 PM | Likes Like |Link to Comment
  • Herbalife (HLF): Q3 EPS of $1.04 beats by $0.03. Revenue of $1.02B (+14% Y/Y) beats by $60M. (PR[View news story]
    Hopefully the market will be open soon enough for this news to make any meaningful impact.
    Oct 29 05:54 PM | Likes Like |Link to Comment
  • Electric vehicle roundup: 1) Audi (VLKAY.PK) halts plans to develop the R8 e-tron due to high costs. 2) Legal experts see dealer groups only having a slim chance to convince state judges to grant injunctions that will stop Tesla (TSLA +0.3%) from operating retail stores. 3) The Chevrolet Volt gets some publicity when President Obama reveals he took one for a spin on the grounds of the White House. 4) Toyota will introduce new hybrid Lexus models in the U.S. after 2012 YTD hybrid sales beat expectations. [View news story]
    Have there been any announcements from Toyota regarding new Lexus hybrid models? Will they be adding hybrid options to the models that they already offer or are they only adding different styles to the current hybrid models?
    Oct 25 04:59 PM | Likes Like |Link to Comment
  • Amarin (AMRN +1.6%) bucks a weak tape this morning after saying that the USPTO has issued two patents covering the use of it's VascepaTM capsules for treating Hypertriglyceridemia. The patent issuance is part of AMRN's effort to protect the commercial potential of the drug through 2030, and it plans to list both patents in the FDA's Orange Book. [View news story]
    Does this mean the NCE status is more likely?
    Oct 23 10:55 AM | Likes Like |Link to Comment
COMMENTS STATS
11 Comments
13 Likes